Study identifier:D7984C00002
ClinicalTrials.gov identifier:NCT06079671
EudraCT identifier:N/A
CTIS identifier:2023-504374-38-00
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
Phase 3
No
-
Female
1000
Interventional
15 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
Gynecologic Oncology Group Foundation, European Network for Gynaecological Oncological Trial groups
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Volrustomig Volrustomig | Biological/Vaccine: Volrustomig IV Infusion Other Name: Volrustomig |
Placebo Comparator: Placebo Placebo | Other: Placebo IV Infusion Other Name: Saline |